 Primary endpoint of phase 3 BEACON study, using tarcocimab tedromer for the treatment of patients with macular edema due to retinal vein occlusion, was met. Four additional studies are expected to have data releases in 2023; GLEAMGLIMMERDAYLIGHTGLOW. 